Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Risk factors associated with brain metastases in ECOG-ACRIN E1505, a phase III randomized trial of adjuvant chemotherapy with or without bevacizumab for patients with completely resected stage IB (>/=4 cm) - IIIA non-small cell lung cancer (NSCLC). Varlotto, J. M., Dahlberg, S., Wakelee, H. A., Ramalingam, S. S., Schiller, J. H. AMER SOC CLINICAL ONCOLOGY. 2017
View details for DOI 10.1200/JCO.2017.35.15_suppl.8539
View details for Web of Science ID 000411932201117